Tags Archives: COVID-19

Perfusfind S.L.

Abstract OBJECTIVES:  The study investigated the impact of prone positioning during venovenous extracorporeal membrane oxygenation support for coronavirus disease 2019 acute respiratory failure on the patient outcome. DESIGN:  An observational..

Perfusfind S.L.

Abstract Introduction The COVID-19 pandemic has had a significant impact on global surgery. In particular, deleterious effects of SARS-CoV-2 infection on the heart and cardiovascular system have been described. To..

Perfusfind S.L.

Abstract Introduction Although extracorporeal membrane oxygenation (ECMO) has been associated with improved outcomes in COVID patients with respiratory failure, data regarding the need for blood product utilization in this population..

Perfusfind S.L.

Abstract One of the hallmarks of the SARS-CoV-2 infection has been the inflammatory process that played a role in its pathogenesis, resulting in mortality within susceptible individuals. This uncontrolled inflammatory..

Perfusfind S.L.

Abstract Anticoagulation during extracorporeal membrane oxygenation (ECMO) for Coronovirus Disease 2019 (COVID-19) can be performed by direct or indirect thrombin inhibitors but differences in outcomes with these agents are uncertain...

Perfusfind S.L.

Abstract Tocilizumab is known to improve outcomes in patients with severe coronavirus disease 2019 (COVID-19) pneumonia. However, little is known about its utility in patients with COVID-19 who require respiratory..

Perfusfind S.L.

Abstract Refractory hypoxemia despite the use of extracorporeal membrane oxygenation (ECMO) for coronavirus disease 2019 (COVID-19)–related acute respiratory distress syndrome remains a challenging problem. A single ECMO circuit may not..

Perfusfind S.L.

Abstract Objectives:  The use of extracorporeal membrane oxygenation (ECMO) in patients with COVID-19 has been supported by major healthcare organizations, yet the role of specific management strategies during ECMO requires..

Perfusfind S.L.

Abstract A retrospective study was performed examining the trend of inflammatory markers, including D-dimers, in 29 COVID-19 patients requiring veno-venous (VV) extracorporeal membrane oxygenation (ECMO) support. We observed that COVID-19..

Perfusfind S.L.

Abstract Coronavirus disease 2019 (COVID-19) has drastically increased the number of patients requiring extracorporeal life support. We investigate the efficacy and safety of low-dose recombinant tissue-type plasminogen activator (rtPA) injection..

Perfusfind S.L.

Abstract As the COVID-19 pandemic goes on, we continue to identify the long-term complications or symptoms among patients who recovered from this infection, be it mild or severe.    These..

Perfusfind S.L.

Abstract Background Extracorporeal membrane oxygenation (ECMO) has been used extensively for coronavirus disease 2019 (COVID-19)-related acute respiratory distress syndrome (ARDS). Reports early in the pandemic suggested that mortality in patients..

Perfusfind S.L.

Summary Current knowledge regarding mechanisms underlying cardiovascular complications in patients with COVID-19 is limited and urgently needed. We shed light on a previously unrecognized mechanism and unravel a key role..

Perfusfind S.L.

Abstract Coronavirus disease 2019 (COVID-19) has increased the demand for extracorporeal membrane oxygenation (ECMO) and introduced distinct challenges to patient selection for ECMO. Standardized processes for patient selection amidst resource..

Perfusfind S.L.

Abstract Background We reviewed our experience with 505 patients with confirmed coronavirus disease-2019 (COVID-19) supported with extracorporeal membrane oxygenation (ECMO) at 45 hospitals and estimated risk factors for mortality. Methods..

Perfusfind S.L.

Abstract For patients with severe acute respiratory distress syndrome (ARDS), receipt of ECMO(1) may improve survival. During the COVID-19 pandemic, the number of patients with COVID-19 referred for ECMO has..

Perfusfind S.L.

Abstract Infection of surgical wounds with acid-fast bacilli, including tubercle bacilli, is rare, and is poorly described in the literature. We present the case of a 74-year-old male who developed..

Perfusfind S.L.

Abstract Veno-venous extracorporeal membrane oxygenation (ECMO) support surged during the COVID-19 pandemic. Our program changed the model of care pursuing to protect the multidisciplinary team from the risk of infection..

Perfusfind S.L.

Abstract Venovenous extracorporeal membrane oxygenation (VV-ECMO) has been used during the COVID-19 pandemic to support patients with the most severe cases of COVID-19 acute respiratory distress syndrome (ARDS). The earliest..

Perfusfind S.L.

Abstract Objective Myocardial damage occurs in up to 25% of coronavirus disease 2019 (COVID-19) cases. While veno-venous extracorporeal life support (V-V ECLS) is used as respiratory support, mechanical circulatory support..

Perfusfind S.L.

Abstract Objective To estimate the effect of extracorporeal membrane oxygenation (ECMO) compared with conventional mechanical ventilation on outcomes of patients with covid-19 associated respiratory failure. Design Observational study. Setting 30 countries across five..

Perfusfind S.L.

Abstract Few patients with coronavirus disease 2019–associated severe acute respiratory distress syndrome (ARDS) require veno-venous extracorporeal membrane oxygenation (VV-ECMO). Prolonged VV-ECMO support necessitates repeated oxygenator replacement, increasing the risk for..

Perfusfind S.L.

Abstract BACKGROUND  In the context of the coronavirus disease 2019 (COVID-19) pandemic, many retrospective single-centre or specialised centre reports have shown promising mortality rates with the use of extracorporeal membrane..

Perfusfind S.L.

Abstract Where is the imperceptible difference? With great interest, we read the recent article by Whebell and colleagues [1] and were appealed by the beneficial effect of extracorporeal membrane oxygenation..

Perfusfind S.L.

Abstract We present a case of acute respiratory distress syndrome (ARDS) secondary to COVID-19 who required venovenous extracorporeal membrane oxygenation (V-V ECMO). Initially, a right ventricular assist device (RVAD), the..

Perfusfind S.L.

Abstract In late 2020, during the second wave of COVID-19 in Germany, we started using the MobyBox, which is a novel fully pneumatically driven ECMO device, on a regular basis..

Perfusfind S.L.

Abstract Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and lung involvement is common. Patients with COVID-19 may progress to acute respiratory distress syndrome..

Perfusfind S.L.

Abstract BACKGROUND: Coronavirus disease 2019 (COVID-19) has a tremendous impact on the respiratory tract. In severe COVID-19 infections, patients may experience shock and multiple organ failure. We described 4 cases of..

Perfusfind S.L.

Abstract Novel Coronavirus Disease in most cases produces mild symptoms which resolve after a few days. Some authors hypothesized that SARS-CoV-2 infection could trigger excessive cytokine production leading to a..

Perfusfind S.L.

Abstract Objectives In addition to excess mortality due to COVID-19, the pandemic has been characterised by excess mortality due to non-COVID diagnoses and consistent reports of patients delaying seeking medical..